提奥胺诱导的急性肝损伤通过降低脏OCT2和MATE1表达和功能的下调来增加美特福林血暴露
Hao Zhi1, Yidong Dai1, Lin Su1
1Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Biomedicines
|December 23, 2023
概括
乙诱导的小鼠肝衰竭会损害脏有机阴离子载体2 (OCT2) 和多药和毒素挤出1 (MATE1) 功能,增加甲胺的血暴露. 升高的雌激素和瘤亡因子-α调节了这种输送器下调.
科学领域:
- 药理动力学和药物新陈代谢
- 肝病学和肝脏疾病.
- 脏生理学和运输
背景情况:
- 甲胺的药理动力学受到有机阴离子载体 (OCT) 和多药物和毒素挤出载体 (MATE) 的影响.
- 肝衰竭可以改变药物暴露,但涉及输送物的具体机制尚不清楚.
研究的目的:
- 为了研究底层的机制增加的甲血暴露在乙胺 (TAA) 诱导的肝衰竭.
- 评估肝功能衰竭对通过OCT和MATE调节的甲福胺吸收和分泌的影响.
主要方法:
- 在TAA诱导的肝衰竭大鼠中进行肠道输液和尿液分泌测定.
- 西部涂抹,以评估甲运输体表达的变化 (OCT2,MATE1).
- 使用HK-2细胞进行体外研究,以探索调节机制.
主要成果:
- 由于TAA引起的肝衰竭并没有显著改变肠道OCT2表达或甲福林吸收.
- 在TAA大鼠中观察到性OCT2和MATE1的显著下调和功能损害,导致甲胺分泌减少.
- 在实验室中,提高雌激素水平和瘤亡因子α被确定为脏OCT2和MATE1下调的关键媒介.
结论:
- 肝损伤会降低脏OCT2和MATE1的表达和功能.
- 这种对运输体的下调有助于在肝衰竭中增加甲胺血暴露.
- 在急性肝衰竭期间,雌激素和TNF-α在调节输送器功能障碍方面发挥着关键作用.
相关概念视频
Phase II Reactions: Acetylation Reactions
229
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
229
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Phase II Reactions: Glucuronidation
444
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
444
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
249
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
249
Dipeptidyl Peptidase 4 Inhibitors
189
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
189
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
179
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
179


